Why is Astrazeneca Phar falling/rising?

As of 24-Jun, Astrazeneca Pharma India Ltd is experiencing a decline in its stock price, currently at Rs 8,747.00, reflecting a decrease of Rs 135.3 or 1.52%. The stock has been underperforming, having fallen consecutively for the last seven days, resulting in a total decline of 16.89% during this period. Today's performance indicates that it has underperformed its sector by 1.73%, with an intraday low of Rs 8,680.15. Despite a strong performance over the longer term, with a 38.42% return over the past year and consistent positive results in recent quarters, the stock's recent downturn is influenced by a combination of falling investor participation and a decline in delivery volume by 28.78% against the five-day average.
In the broader market context, the stock's short-term performance contrasts sharply with the benchmark Sensex, which has increased by 0.58% over the past week. While Astrazeneca Pharma has shown impressive long-term growth, including a 220.22% return over three years, concerns about its valuation, as indicated by a high Price to Book Value ratio and a declining stake from institutional investors, may be contributing to the current price drop. The company's operating profit growth rate of 15.95% over the last five years also raises questions about its long-term growth potential, further impacting investor sentiment.